300347 泰格医药
已收盘 02-27 15:00:00
资讯
新帖
简况
东吴证券：给予泰格医药买入评级
证券之星 · 02-15
东吴证券：给予泰格医药买入评级
里昂：降泰格医药(03347)目标价至59.9港元 续予“跑赢大市”评级
智通财经 · 02-12
里昂：降泰格医药(03347)目标价至59.9港元 续予“跑赢大市”评级
港股异动 | 泰格医药(03347)尾盘跌超5% 扣非利润下跌逾四成 机构称股价已反映利好因素
智通财经 · 02-12
港股异动 | 泰格医药(03347)尾盘跌超5% 扣非利润下跌逾四成 机构称股价已反映利好因素
扣非归母净利润下跌逾40%，泰格医药(03347)何以在二级市场量价齐升？
智通财经 · 02-10
扣非归母净利润下跌逾40%，泰格医药(03347)何以在二级市场量价齐升？
泰格医药新注册《泰格医药支撑安全性报告分发和接收系统V1.0》项目的软件著作权
证券之星 · 02-09
泰格医药新注册《泰格医药支撑安全性报告分发和接收系统V1.0》项目的软件著作权
泰格医药新注册《泰格医药支撑远程监查系统V1.0》项目的软件著作权
证券之星 · 02-07
泰格医药新注册《泰格医药支撑远程监查系统V1.0》项目的软件著作权
泰格医药涨超4% 公司新增订单强劲 管理层对CRO前景保持乐观
智通财经 · 02-03
泰格医药涨超4% 公司新增订单强劲 管理层对CRO前景保持乐观
泰格医药（300347）披露关于变更公司注册地址及修订公司章程的公告，2月2日股价下跌4.44%
证券之星 · 02-02
泰格医药（300347）披露关于变更公司注册地址及修订公司章程的公告，2月2日股价下跌4.44%
1月30日泰格医药涨6.96%，中欧医疗健康混合A基金重仓该股
证券之星 · 01-30
1月30日泰格医药涨6.96%，中欧医疗健康混合A基金重仓该股
瑞银：泰格医药(03347)去年纯利逊预期 关注今年新签订单价格复苏
智通财经网 · 01-30
瑞银：泰格医药(03347)去年纯利逊预期 关注今年新签订单价格复苏
大摩：看好泰格医药(03347)新订单增长强劲 集团管理层对行业前景保持乐观
智通财经 · 01-30
大摩：看好泰格医药(03347)新订单增长强劲 集团管理层对行业前景保持乐观
高盛：升泰格医药(03347)目标价至66.4港元 预计订单势头将复苏
智通财经 · 01-30
高盛：升泰格医药(03347)目标价至66.4港元 预计订单势头将复苏
泰格医药：2025年净利同比预增105%~204%
每日经济新闻 · 01-29
泰格医药：2025年净利同比预增105%~204%
上海市浙江商会轮值会长交接，泰格医药董事长叶小平获任
睿见Economy · 01-18
上海市浙江商会轮值会长交接，泰格医药董事长叶小平获任
泰格医药（300347）披露证券变动月报表，1月6日股价下跌0.32%
证券之星 · 01-06
泰格医药（300347）披露证券变动月报表，1月6日股价下跌0.32%
市值蒸发超千亿，深证100“踢群”泰格医药
视频滚动新闻 · 2025-12-18
市值蒸发超千亿，深证100“踢群”泰格医药
主业疲软、投资“撑场”：CRO龙头泰格医药指数“光环”褪色，千亿市值因何蒸发？
华夏时报网 · 2025-12-17
主业疲软、投资“撑场”：CRO龙头泰格医药指数“光环”褪色，千亿市值因何蒸发？
重要指数样本股调整，泰格医药黯然离场，1350亿市值已烟消云散
深圳商报·读创 · 2025-12-14
重要指数样本股调整，泰格医药黯然离场，1350亿市值已烟消云散
泰格医药（300347）披露第五届董事会审计委员会成员及召集人，12月11日股价下跌1.4%
证券之星 · 2025-12-11
泰格医药（300347）披露第五届董事会审计委员会成员及召集人，12月11日股价下跌1.4%
泰格医药（300347）新增【AIGC】概念
证券之星 · 2025-12-04
泰格医药（300347）新增【AIGC】概念
加载更多
公司概况
公司名称：
杭州泰格医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2012-08-17
主营业务：
杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查与培训、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室。
发行价格：
37.88
{"stockData":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":59.64,"timestamp":1772175825000,"preClose":60.5,"halted":0,"volume":6184204,"delay":0,"changeRate":-0.0142,"floatShares":566000000,"shares":861000000,"eps":0.711,"marketStatus":"已收盘","change":-0.86,"latestTime":"02-27 15:00:00","open":60.18,"high":61.15,"low":59.42,"amount":371000000,"amplitude":0.0286,"askPrice":59.64,"askSize":103,"bidPrice":59.63,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.711,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":60.5,"symbolType":"stock","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":66.55,"lowLimit":54.45,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":861026050,"isCdr":false,"pbRate":2.46,"roa":"--","peRate":83.881857,"roe":"4.89%","epsLYR":0.47,"committee":0.104167,"marketValue":51352000000,"turnoverRate":0.0109,"status":1,"hkstockBrief":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":47.06,"timestamp":1772179700006,"preClose":47.38,"halted":0,"volume":789649,"delay":0,"premium":"-30.76"},"floatMarketCap":33769000000},"requestUrl":"/m/hq/s/300347","defaultTab":"news","newsList":[{"id":"2611429171","title":"东吴证券：给予泰格医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2611429171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611429171?lang=zh_cn&edition=full","pubTime":"2026-02-15 09:10","pubTimestamp":1771117827,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对泰格医药进行研究并发布了研究报告《泰格医药：临床CRO龙头，扬帆启航新征程》，给予泰格医药买入评级。国内临床CRO行业经历激烈的价格竞争，供给优化，泰格医药龙头市占率持续提升，新签订单加速，有望迎来量价齐升，业绩修复增长潜力大。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为77.88。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500001037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","03347","601555"],"gpt_icon":0},{"id":"2610912794","title":"里昂：降泰格医药(03347)目标价至59.9港元 续予“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2610912794","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610912794?lang=zh_cn&edition=full","pubTime":"2026-02-12 15:29","pubTimestamp":1770881373,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，下调泰格医药(03347) 2027财年盈测7%，以反映长期投资收益的不确定因素增加。该行续予泰格医药“跑赢大市”评级，当中将H股目标价由68.2港元下调至59.9港元，并将泰格医药(300347.SZ)A股目标价由81.9元人民币降至72元人民币。泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","300347"],"gpt_icon":0},{"id":"2610691478","title":"港股异动 | 泰格医药(03347)尾盘跌超5% 扣非利润下跌逾四成 机构称股价已反映利好因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2610691478","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610691478?lang=zh_cn&edition=full","pubTime":"2026-02-12 15:12","pubTimestamp":1770880368,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，泰格医药尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港元。消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。该行下调泰格医药2027财年盈测7%，以反映长期投资收益的不确定因素增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","VXUS","BK0174","LU1820825898.SGD","LU1146622755.USD","BK4585","BK0077","BK4588","03347","BK0028","BK1141","VT","300347","BK1576","BK1583"],"gpt_icon":0},{"id":"2610613952","title":"扣非归母净利润下跌逾40%，泰格医药(03347)何以在二级市场量价齐升？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610613952","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610613952?lang=zh_cn&edition=full","pubTime":"2026-02-10 14:21","pubTimestamp":1770704466,"startTime":"0","endTime":"0","summary":"近日， 泰格医药的股价出现了一波明显的止跌反弹的趋势。但之后，泰格医药股价又迎来近半个月的技术性下跌，于1月28日跌破50港元。而导致这一盘面变化的根本原因或在于泰格医药披露的2025年年报业绩预告。并且当日是一个典型的“量价齐升”走势，泰格医药当日股票成交量达到704.77万股，展示出场外持币投资者较为强烈的买入意愿。而这已初步反映在了泰格医药此次披露的业绩预告中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","300347"],"gpt_icon":0},{"id":"2610577598","title":"泰格医药新注册《泰格医药支撑安全性报告分发和接收系统V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2610577598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610577598?lang=zh_cn&edition=full","pubTime":"2026-02-09 01:51","pubTimestamp":1770573072,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰格医药新注册了《泰格医药支撑安全性报告分发和接收系统V1.0》项目的软件著作权。今年以来泰格医药新注册软件著作权2个，较去年同期减少了33.33%。通过天眼查大数据分析，杭州泰格医药科技股份有限公司共对外投资了59家企业，参与招投标项目53次；财产线索方面有商标信息79条，专利信息17条，著作权信息177条；此外企业还拥有行政许可45个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900000886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","LU1146622755.USD","BK1583","03347","BK0216","300347","BK0077","BK0174","BK1141","LU1820825898.SGD","BK1576"],"gpt_icon":0},{"id":"2609651585","title":"泰格医药新注册《泰格医药支撑远程监查系统V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2609651585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609651585?lang=zh_cn&edition=full","pubTime":"2026-02-07 02:13","pubTimestamp":1770401591,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰格医药（300347）新注册了《泰格医药支撑远程监查系统V1.0》项目的软件著作权。今年以来泰格医药新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1.27亿元，同比增1.85%。通过天眼查大数据分析，杭州泰格医药科技股份有限公司共对外投资了59家企业，参与招投标项目53次；财产线索方面有商标信息79条，专利信息17条，著作权信息177条；此外企业还拥有行政许可45个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020700000210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","BK0028","03347","BK0216","BK1576","BK1583","BK0077","LU1146622755.USD","BK1141","BK0174","LU1820825898.SGD"],"gpt_icon":0},{"id":"2608817433","title":"泰格医药涨超4% 公司新增订单强劲 管理层对CRO前景保持乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=2608817433","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608817433?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:07","pubTimestamp":1770084420,"startTime":"0","endTime":"0","summary":"泰格医药(03347)涨超4%，截至发稿，涨4.04%，报52.8港元，成交额2428.77万港元。消息面上，泰格医药近日发盈喜，高盛指出，公司预计2025年收入介乎66.6亿至76.8亿元人民币(下同)，较该行及 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260203/c674506217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0028","300347","LU1820825898.SGD","BK0216","BK0077","LU1146622755.USD","BK0174"],"gpt_icon":0},{"id":"2608867266","title":"泰格医药（300347）披露关于变更公司注册地址及修订公司章程的公告，2月2日股价下跌4.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608867266","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608867266?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:29","pubTimestamp":1770042559,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，泰格医药报收于60.21元，较前一交易日下跌4.44%，最新总市值为518.42亿元。近日，杭州泰格医药科技股份有限公司发布《关于变更公司注册地址及修订公司章程的公告》。公告显示，公司于2026年2月2日召开第五届董事会第二十一次会议，审议通过《关于变更公司注册地址及修订<公司章程>的议案》。董事会提请股东大会授权办理相关工商变更登记手续。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1146622755.USD","BK0028","LU1820825898.SGD","BK0174","BK1583","300347","BK0216","BK0077","BK1576","BK1141","03347"],"gpt_icon":0},{"id":"2607090920","title":"1月30日泰格医药涨6.96%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607090920","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607090920?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:42","pubTimestamp":1769762528,"startTime":"0","endTime":"0","summary":"证券之星消息，1月30日泰格医药涨6.96%创60日新高，收盘报63.01元，换手率4.07%，成交量23.05万手，成交额14.75亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共96家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.799，较上一交易日上涨0.56%，近一年上涨19.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000028025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","BK0028","300347","BK0077","BK0216","BK1583","LU1820825898.SGD","BK1141","BK1576","BK0174","03347","LU1146622755.USD"],"gpt_icon":0},{"id":"2608507077","title":"瑞银：泰格医药(03347)去年纯利逊预期 关注今年新签订单价格复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2608507077","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608507077?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:56","pubTimestamp":1769759765,"startTime":"0","endTime":"0","summary":"现予泰格医药(03347)目标价57.1港元及“买入”评级。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260130/20260130155838_52529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260130/20260130155838_52529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03347","BK0216","BK1141","BK1583","LU1146622755.USD","BK0174","BK0077","BK0028","BK1576","300347","LU1820825898.SGD"],"gpt_icon":0},{"id":"2607094725","title":"大摩：看好泰格医药(03347)新订单增长强劲 集团管理层对行业前景保持乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=2607094725","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607094725?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:34","pubTimestamp":1769758474,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，泰格医药公布2025年初步业绩，营收介乎为66.6亿元至76.8亿元人民币(下同)，同比增长1%至16%。该范围较摩根士丹利预估为低2%至高12%。予泰格医药A股目标价81元，评级“增持”。摩根士丹利表示，强劲的盈利增长主要归因于泰格医药资产的大幅重估，以及2024年相对较低的基数。大摩又指，集团管理层对行业前景保持乐观，而近期的一次会议上，管理层提到中国CRO行业似乎正处于复苏态势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","300347","BK1576","BK0174","BK1141","LU1820825898.SGD","BK1583","BK0028","BK0216","03347","LU1146622755.USD"],"gpt_icon":0},{"id":"2607093352","title":"高盛：升泰格医药(03347)目标价至66.4港元 预计订单势头将复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607093352","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607093352?lang=zh_cn&edition=full","pubTime":"2026-01-30 13:40","pubTimestamp":1769751635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，将泰格医药2025至2027年盈利预测分别下调29%、上调2%及上调2%，将泰格医药H股目标价由63.4港元微升至66.4港元，泰格医药A股 目标价由78.7元人民币升至82.5元人民币，均予“买入”评级。泰格医药公布盈利预告，预计2025年收入介乎66.6亿至76.8亿元人民币(下同)，较该行及市场预期高。经常性净利润介乎3.3亿至4.9亿元，则逊该行及市场预期，主要由于减值拨备高于预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300347","03347"],"gpt_icon":0},{"id":"2607704786","title":"泰格医药：2025年净利同比预增105%~204%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704786","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704786?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:54","pubTimestamp":1769676883,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月29日，泰格医药(300347.SZ)公告称，预计2025年归属于上市公司股东的净利润为8.30亿元~12.30亿元，比上年同期增长105%~204%。业绩变动主要系报告期内非经常性损益大幅增加，公司持有的非流动金融资产（包括非上市公司股权、上市公司股份及医药基金）处置及持有收益显著提升，叠加中国创新药行业复苏带动资产价值修复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601293635289384.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635289384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0174","LU1820825898.SGD","BK0216","LU1146622755.USD","BK1141","BK0028","BK1576","03347","BK0077","300347","BK1583"],"gpt_icon":0},{"id":"2604927177","title":"上海市浙江商会轮值会长交接，泰格医药董事长叶小平获任","url":"https://stock-news.laohu8.com/highlight/detail?id=2604927177","media":"睿见Economy","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604927177?lang=zh_cn&edition=full","pubTime":"2026-01-18 15:21","pubTimestamp":1768720860,"startTime":"0","endTime":"0","summary":" “第九届世界浙商上海论坛暨2025上海市浙江商会年会”于1月18日在上海举行。会上举行了轮值会长交接仪式。上海市浙江商会2025年度轮值会长、晶科能源董事长李仙德将旗帜交于2026年度轮值会长、泰格医药董事长叶小平手中。 据介绍，叶小平深耕生物医药领域二十多年，创办的泰格医药作为全球化研发平台，为50多个国家医学事业进步提供了强劲助力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-01-18/doc-inhhthyt3571509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0174","BK1576","BK1583","LU1146622755.USD","BK0216","LU1820825898.SGD","300347","BK0077","03347","BK1141"],"gpt_icon":0},{"id":"2601136618","title":"泰格医药（300347）披露证券变动月报表，1月6日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601136618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601136618?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:18","pubTimestamp":1767709099,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，泰格医药报收于58.98元，较前一交易日下跌0.32%，最新总市值为507.83亿元。A股和H股的法定股份数目分别为737,901,250股和123,124,800股，面值均为人民币1元。已发行股份总数无变动，其中A股已发行股份为732,017,470股，库存股为5,883,780股，H股已发行股份为123,124,800股，无库存股。公告显示，公司于2024年至2025年期间多次购回A股并持有为库存股份，并于2025年5月注销部分库存股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","03347","BK1141","BK1583","LU1146622755.USD","161027","LU1820825898.SGD","300347","BK1576","BK0174","BK0077","BK0028"],"gpt_icon":0},{"id":"2592908047","title":"市值蒸发超千亿，深证100“踢群”泰格医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908047","media":"视频滚动新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592908047?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:56","pubTimestamp":1766058960,"startTime":"0","endTime":"0","summary":"12月15日，泰格医药被调出深证100成分股，结束6年指数生涯。尽管其2025年前三季度净利润同比涨20.88%，但股价逆市下跌6.7%，市值从1700亿高点跌至430亿左右，收入规模、营收增速、ROE等指标也逊于深证100平均水平。资金方面，高管持续减持，公募基金持仓大降。不过，部分机构仍唱多。此外，泰格医药投资布局广，但近期业绩承压、流动性告急，开始退出项目回笼资金，虽净利润反转，但市场并不买账，重拾信心或取决于主业盈利能力修复。(AI生成)\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-12-18/doc-inhcfrcf8410958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","03347","BK1141","BK1583","LU1146622755.USD","LU1820825898.SGD","399330","300347","BK1576","BK0174","BK0077","BK0028","161227"],"gpt_icon":0},{"id":"2592291364","title":"主业疲软、投资“撑场”：CRO龙头泰格医药指数“光环”褪色，千亿市值因何蒸发？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592291364","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592291364?lang=zh_cn&edition=full","pubTime":"2025-12-17 21:45","pubTimestamp":1765979156,"startTime":"0","endTime":"0","summary":"国内临床CRO龙头企业泰格医药（300347.SZ）于12月15日起正式被调出深证100成份股，结束了自2019年12月纳入以来长达六年的指数生涯。此次调整正值CRO行业因“猴荒”再现迎来普涨行情，板块内多数企业股价上行。然而，泰格医药走势却与行业背离，成为板块中唯一的“失意者”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512173594505571.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512173594505571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1146622755.USD","BK1576","BK1583","BK0077","03347","300347","BK1141","LU1820825898.SGD","BK0216","BK0174"],"gpt_icon":0},{"id":"2591657113","title":"重要指数样本股调整，泰格医药黯然离场，1350亿市值已烟消云散","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657113","media":"深圳商报·读创","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657113?lang=zh_cn&edition=full","pubTime":"2025-12-14 15:06","pubTimestamp":1765696006,"startTime":"0","endTime":"0","summary":"国内临床CRO龙头泰格医药(300347)，即将被调出深证100指数样本股，其市值较高点已蒸发1350亿元。日前，深圳证券交易所及深圳证券信息有限公司发布公告，根据指数编制规则，将对深证成指、创业板指、深证100、创业板50等深市指数实施样本定期调整。本次调整将于12月15日正式实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512143590930292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","LU1820825898.SGD","03347","BK1583","LU1146622755.USD","BK0028","BK0174","BK0216","BK1141","BK0077","300347"],"gpt_icon":0},{"id":"2590591678","title":"泰格医药（300347）披露第五届董事会审计委员会成员及召集人，12月11日股价下跌1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590591678","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590591678?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:44","pubTimestamp":1765446288,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，泰格医药报收于49.19元，较前一交易日下跌1.4%，最新总市值为423.54亿元。公司近日发布公告称，杭州泰格医药科技股份有限公司于2025年12月9日召开第五届董事会第二十次会议，审议通过《关于确认公司第五届董事会审计委员会成员及召集人的议案》。公告显示，第五届董事会审计委员会由廖启宇先生、袁华刚先生、刘毓文女士组成，召集人为廖启宇先生，任期自董事会审议通过之日起至第五届董事会届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100028560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","BK0216","BK1141","BK1583","03347","BK0028","BK1576","LU1820825898.SGD","BK0077","BK0174","LU1146622755.USD"],"gpt_icon":0},{"id":"2588881150","title":"泰格医药（300347）新增【AIGC】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588881150?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:30","pubTimestamp":1764851432,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，12月4日泰格医药新增概念。该公司关联的其它概念板块还包括：AI医疗概念、CXO概念、创新药。泰格医药主营业务：临床试验技术服务和临床试验相关服务及实验室服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400036136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0216","BK1141","LU1820825898.SGD","BK1583","300347","LU1146622755.USD","03347","BK0028","BK0077","BK0174"],"gpt_icon":1}],"profile":{"ret":0,"serverTime":1772338174571,"stockEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":0.048},{"period":"3month","weight":0.1692},{"period":"6month","weight":-0.0609},{"period":"1year","weight":0.008},{"period":"ytd","weight":0.0519}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州泰格医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2012-08-17","address":"浙江省杭州市滨江区西兴街道聚工路19号8幢20层2001-2010室","registeredCapital":"86102万元","survey":" 杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查与培训、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,300347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}